It would hence be reasonable to co-assess the genomic and immune phenotypic statuses of PCNSL to propose combined ibrutinib/ICI therapies to immune rich/MYD88-mutated PCNSL patients (ongoing trial NCT03770416). The gene discussed is MYD88; the disease is primary central nervous system lymphoma.